Trial Profile
A first-in-human, randomized, placebo-controlled, dose escalation Phase 1/2 clinical trial of AT-001 in patients with Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Jul 2020
Price :
$35
*
At a glance
- Drugs Caficrestat (Primary)
- Indications Diabetic cardiomyopathy; Heart failure; Myocardial infarction; Peripheral nervous system diseases
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Proof of concept
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association
- 11 Jun 2019 Results presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
- 07 Jun 2019 Results published in the Applied Therapeutics Media Release.